"10.1371_journal.pone.0104001","plos one","2014-08-04T00:00:00Z","Carl I Webster; Matthew Burrell; Lise-Lotte Olsson; Susan B Fowler; Sarah Digby; Alan Sandercock; Arjan Snijder; Jan Tebbe; Ulrich Haupts; Joanna Grudzinska; Lutz Jermutus; Christin Andersson","Antibody Discovery and Protein Engineering, MedImmune, Cambridge, United Kingdom; Discovery Sciences, AstraZeneca R & D, Mölndal, Sweden; Global Drug Discovery, Global Biologics, Bayer HealthCare AG, Cologne, Germany; CNS&P iMed, AstraZeneca R & D, Södertälje, Sweden","Conceived and designed the experiments: CW LJ MB UH JT CA SF A. Snijder A. Sandercock L-LO. Performed the experiments: MB JT SD L-LO A. Sandercock JG SF. Analyzed the data: CW CA LJ MB SF UH JT L-LO A. Sandercock A. Snijder. Wrote the paper: CW MB A. Snijder L-LO JT.","This study was funded by AstraZeneca and MedImmune. At the time of performing the work all of the authors were affiliated to one of the commercial organisations, AstraZeneca, MedImmune, or Bayer Healthcare. Some of the authors are also co-inventors on a patent describing the mutants to neprilysin, but receive no financial benefit from this beyond their normal terms of employment. Patent name “Protease Variants” and number US20120237496. Authors affiliated with AstraZeneca or MedImmune may hold stock or stock options in AstraZeneca and authors affiliated with Bayer Healthcare may hold stock or stock options in Bayer Healthcare. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","08","Carl I Webster","CIW",12,TRUE,8,5,9,3,TRUE,TRUE,TRUE,1,"10",FALSE
